Guccini et al. show that TIMP1 loss switches senescence from a tumor-suppressive to a pro-metastatic process in prostate cancer mouse models. Pharmacological targeting of TIMP1-deficient senescent tumor cells impedes metastases in mice, thereby validating the therapeutic potential of senolytic therapy in prostate cancer.
from Cancer Cell https://ift.tt/3luID96
from Cancer Cell https://ift.tt/3luID96